This scanning electron microscope image shows the T cell-trapping biomaterial up-close with cavities and ducts allowing the entry, as well as movement and binding of autoimmune T cells in its interior. Photo courtesy of James Weaver.
Adapted from a Joslin Diabetes Center press release
Diabetes researchers have puzzled for decades about why insulin-producing beta cells in one pancreatic islet often look and behave quite differently than their counterparts in the same islet or in nearby islets. Using newly identified cellular markers of aging, Joslin Diabetes Center scientists now have shown that this diversity may be driven at least in part by differently aged beta cell populations within the pancreas.
Cambridge, MA, June 16,2016 - The Harvard Stem Cell Institute, three of Harvard’s clinical affiliates, and a biopharmaceutical company have formed a unique collaboration to establish the Boston Autologous Islet Replacement Program (BAIRT) to accelerate a cure for diabetes.
Stem cell-derived, glucose-stimulated, insulin-producing cells (SC-β) are protected inside capsules engineered to be invisible to the host immune system. Photo courtesy of Omid Veiseh and Andrew Bader/Anderson/Langer Laboratory, Koch Institute at MIT
Harvard researchers have created a system using human stem cells to screen for compounds that have the potential to turn white, or “bad,” fat cells into brown, or “good,” fat cells. Pictured are human pluripotent stem cell-derived fat cells. (Photo Credit Tim Ahfeldt/ Read more about A pill to shed fat?